Plant Name: Rheum undulatum
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| PTPN1; CDC25B; | |
| HDAC2; HDAC8; | |
| RECQL; TDP1; BLM; PIK3CA; PIK3CB; HPGD; ALOX12; GFER; HSD17B10; ALOX15; NQO2; ALDH1A1; POLB; | |
| PIM1; MAPK1; BCR; SYK; CSNK2A1; | |
| CA2; CA1; CA12; CA9; CA13; CA7; CA3; CA14; CA5B; CA5A; CA4; CA6; | |
| ESR1; ESR2; | |
| TYR; MAOA; PTGS2; PTGS1; | |
| KDM4E; | |
| ELANE; | |
| HIF1A; TP53; | |
| FUT7; | |
| ABCB1; | |
| SLC6A2; | |
| HTT; NPC1; LMNA; MAPT; GMNN; APP; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
| Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Histone deacetylase | HDAC2 | Histone deacetylase 2 | Q92769 | CHEMBL1937 |
| Histone deacetylase | HDAC8 | Histone deacetylase 8 | Q9BY41 | CHEMBL3192 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | BCR | Bcr/Abl fusion protein | P11274 | CHEMBL2096618 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Serine protease | ELANE | Leukocyte elastase | P08246 | CHEMBL248 |
| SLC superfamily of solute carriers | SLC6A2 | Norepinephrine transporter | P23975 | CHEMBL222 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | GMNN | Geminin | O75496 | CHEMBL1293278 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 7.192E-11 | 8.700E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 4.313E-10 | 3.757E-07 | BLM, CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, NQO2, PTPN1, TP53 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.436E-09 | 1.117E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.652E-09 | 3.517E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.304E-09 | 3.710E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 7.469E-09 | 4.280E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, PTGS1, PTGS2 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 4.150E-08 | 1.819E-05 | CA2, CA7, HIF1A, HTT, MAPK1, NPC1, PIK3CB, PTGS2, SYK |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 4.301E-08 | 1.819E-05 | ALOX12, ALOX15, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 4.671E-08 | 1.919E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.257E-07 | 4.414E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 1.701E-07 | 5.699E-05 | ALOX12, ALOX15, HPGD, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 5.527E-07 | 1.719E-04 | CYP1A1, HDAC2, POLB, TP53 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 8.138E-07 | 2.428E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:2000377; regulation of reactive oxygen species metabolic process | 1.137E-06 | 3.215E-04 | BCR, CYP1B1, HIF1A, MAPT, PTGS2, SYK, TP53 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 2.516E-06 | 6.088E-04 | CA2, CA7, HDAC8, HIF1A, HTT, MAPK1, NPC1, PIK3CB, PTGS2, SYK |
| BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 2.609E-06 | 6.175E-04 | BLM, RECQL, TP53 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 3.234E-06 | 7.573E-04 | CSNK2A1, HDAC8, HIF1A, MAPT |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 3.719E-06 | 8.614E-04 | ABCB1, CA2, CA7 |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 3.796E-06 | 8.701E-04 | ALOX12, CDC25B, CSNK2A1, ELANE, ESR1, HDAC2, HIF1A, HPGD, MAPK1, PIM1, PTGS2, SYK, TSHR |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.739E-28 | 3.786E-24 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 5.540E-06 | 1.194E-03 | APP, CA12, CA2, CA7, ELANE, ESR1, HIF1A, HTT, MAPK1, PIK3CB, TP53 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 6.787E-06 | 1.407E-03 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.014E-05 | 1.946E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 1.014E-05 | 1.946E-03 | PTGS1, PTGS2 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 1.014E-05 | 1.946E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.014E-05 | 1.946E-03 | ALOX12, ALOX15 |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 1.016E-05 | 1.946E-03 | ALDH1A1, ALOX12, ALOX15, APP, BCR, BLM, CA1, CA13, CA2, CA3, CA7, CDC25B, CSNK2A1, GFER, GMNN, HDAC8, HIF1A, HPGD, HTT, LMNA, MAPK1, MAPT, NQO2, PIK3CA, PIK3CB, PIM1, PTPN1, SMN1, SMN2, SYK, TP53, TYR |
| BP | GO:0009987; cellular process | GO:1902533; positive regulation of intracellular signal transduction | 1.104E-05 | 2.036E-03 | ALOX15, APP, CYP1B1, ELANE, HDAC2, HTT, MAPK1, PIK3CA, PIK3CB, PTGS2, PTPN1, SYK, TP53 |
| BP | GO:0009987; cellular process | GO:0034605; cellular response to heat | 1.299E-05 | 2.299E-03 | HDAC2, MAPT, PTGS2, TP53 |
| BP | GO:0050896; response to stimulus | GO:0006979; response to oxidative stress | 1.337E-05 | 2.347E-03 | APP, CA3, CYP1B1, HDAC2, MAPK1, PTGS1, PTGS2, TP53 |
| CC | GO:0043226; organelle | GO:0043231; intracellular membrane-bounded organelle | 2.121E-05 | 3.447E-03 | APP, BLM, CA13, CA4, CA5A, CA5B, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, ESR1, ESR2, FUT7, GFER, GMNN, HDAC2, HDAC8, HIF1A, HSD17B10, HTT, KDM4E, LMNA, MAOA, MAPK1, MAPT, NPC1, PIK3CB, PIM1, POLB, PTGS1, PTGS2, PTPN1, RECQL, SMN1, SMN2, SYK, TDP1, TP53, TYR |
| BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 2.500E-05 | 3.974E-03 | ALDH1A1, CYP1A1, CYP1B1, CYP3A4, ESR1 |
| BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 2.899E-05 | 4.436E-03 | BCR, CYP1A1, CYP1A2, ELANE, HDAC2, HPGD, PTGS2 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.035E-05 | 4.465E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 3.035E-05 | 4.465E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 3.035E-05 | 4.465E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 3.035E-05 | 4.465E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 3.035E-05 | 4.465E-03 | ALOX12, ALOX15 |
| BP | GO:0065007; biological regulation | GO:0051090; regulation of DNA binding transcription factor activity | 3.233E-05 | 4.686E-03 | APP, CYP1B1, ESR1, ESR2, HDAC2, MAPK1, PIM1, SYK |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 3.249E-05 | 4.686E-03 | BLM, CYP1B1, HDAC2, HDAC8, MAPK1, PTGS2, TP53 |
| BP | GO:0040007; growth | GO:0040008; regulation of growth | 4.054E-05 | 5.695E-03 | ALOX12, APP, CSNK2A1, ELANE, ESR2, HIF1A, MAPT, PIK3CA, PIM1, TP53 |
| BP | GO:0008152; metabolic process | GO:0001934; positive regulation of protein phosphorylation | 4.101E-05 | 5.725E-03 | ALOX15, APP, CDC25B, ELANE, HDAC2, MAPK1, PIK3CA, PIK3CB, PTGS2, PTPN1, SYK, TP53 |
| BP | GO:0023052; signaling | GO:0050806; positive regulation of synaptic transmission | 4.318E-05 | 5.914E-03 | APP, CA2, CA7, MAPK1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 5.327E-05 | 7.073E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 6.057E-05 | 7.735E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 6.057E-05 | 7.735E-03 | ESR1, ESR2 |
| BP | GO:0051179; localization | GO:0030100; regulation of endocytosis | 7.181E-05 | 8.736E-03 | ALOX15, APP, BCR, PIK3CB, PTPN1, SYK |
| BP | GO:0050896; response to stimulus | GO:0006954; inflammatory response | 7.232E-05 | 8.749E-03 | ALOX15, ELANE, PIK3CA, PIK3CB, POLB, PTGS1, PTGS2, SYK |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 7.528E-05 | 9.057E-03 | BLM, HIF1A, HTT, TP53 |
| BP | GO:0008152; metabolic process | GO:0006693; prostaglandin metabolic process | 7.767E-05 | 9.192E-03 | HPGD, PTGS1, PTGS2 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 7.518E-21 | 8.185E-17 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 8.238E-20 | 5.934E-16 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.550E-27 | 2.465E-25 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 6.186E-11 | 4.918E-09 | CYP2C9; APP; MAOA; ALOX15; MAPK1; ALOX12; CYP2C19; PTGS2; PTGS1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.719E-08 | 1.183E-06 | CYP2C9; ALOX15; ALOX12; CYP2C19; PTGS2; PTGS1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 6.151E-09 | 3.260E-07 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 7.821E-08 | 2.072E-06 | HDAC2; PIK3CA; MAPK1; PIK3CB; TP53; ESR1; HIF1A |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.003E-07 | 2.278E-06 | BCR; HDAC2; PIK3CA; MAPK1; PIK3CB; TP53 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 2.236E-07 | 4.444E-06 | POLB; HDAC2; SYK; PIK3CA; MAPK1; PIK3CB; HDAC8; TP53 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 2.723E-08 | 1.082E-06 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 8.215E-07 | 1.451E-05 | PIK3CA; PIK3CB; PTGS2; TSHR; PTGS1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.023E-06 | 2.925E-05 | PIK3CA; MAPK1; PIK3CB; TP53; HIF1A |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.739E-06 | 2.765E-05 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 2.897E-06 | 3.524E-05 | PIK3CA; MAPK1; PIK3CB; ESR1; ESR2 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 3.630E-06 | 3.848E-05 | ABCB1; PIK3CA; PIM1; CYP1B1; MAPK1; PTGS2; TP53; CDC25B |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.344E-06 | 3.105E-05 | CYP2C9; MAOA; CYP1A2; CYP3A4; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 3.103E-06 | 3.524E-05 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.003E-05 | 1.696E-04 | MAOA; ALOX15; ALOX12; PTGS2; CYP2C19; CYP3A4; TYR; HSD17B10; PTGS1; CYP2C9; FUT7; CYP1A2; ALDH1A1; CYP1A1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.389E-05 | 1.299E-04 | PIK3CA; MAPK1; PIK3CB; ESR1; ESR2 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 2.977E-05 | 2.152E-04 | BCR; HDAC2; PIK3CA; MAPK1; PIK3CB; PTGS2; HIF1A; TP53 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 3.784E-05 | 2.209E-04 | HDAC2; SYK; CSNK2A1; PIK3CA; PIK3CB; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 2.725E-05 | 2.152E-04 | PIK3CA; MAPK1; PIK3CB; TP53 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 7.036E-06 | 6.992E-05 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 3.890E-05 | 2.209E-04 | PIK3CA; MAPK1; PIK3CB; TP53; HIF1A; ESR1 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 2.027E-05 | 1.696E-04 | PIK3CA; MAPK1; PIK3CB; TP53 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 3.812E-05 | 2.209E-04 | PIK3CA; SYK; MAPK1; PIK3CB; PTGS1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 2.924E-05 | 2.152E-04 | PIK3CA; PIM1; MAPK1; PIK3CB |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 3.584E-05 | 2.209E-04 | PIK3CA; MAPK1; PIK3CB; HIF1A |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 3.827E-05 | 2.209E-04 | PIK3CA; MAPK1; PIK3CB; PTGS2 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 7.347E-05 | 3.338E-04 | PIK3CA; LMNA; MAPK1; PIK3CB; TP53 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 4.919E-05 | 2.596E-04 | PIK3CA; MAPK1; PIK3CB; TP53 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 3.133E-05 | 2.166E-04 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 4.082E-05 | 2.238E-04 | PIK3CA; MAPK1; PIK3CB; TP53 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 5.876E-05 | 2.831E-04 | PIK3CA; SYK; MAPK1; PIK3CB |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 5.225E-05 | 2.596E-04 | PIK3CA; MAPK1; PIK3CB; TP53 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 5.225E-05 | 2.596E-04 | PIK3CA; MAPK1; PIK3CB; HIF1A |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 6.963E-05 | 3.256E-04 | PIK3CA; MAPK1; PIK3CB; TP53 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 7.763E-05 | 3.429E-04 | PIK3CA; SYK; MAPK1; PIK3CB |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.678E-04 | 7.022E-04 | PIK3CA; MAPK1; PIK3CB; TP53 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 2.730E-04 | 1.009E-03 | PIK3CA; PIM1; MAPK1; PIK3CB |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 2.432E-04 | 9.431E-04 | PIK3CA; MAPK1; PIK3CB; CDC25B |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.470E-04 | 6.316E-04 | PIK3CA; PIK3CB; PTGS2; TP53 |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 1.988E-04 | 8.107E-04 | PIK3CA; SYK; MAPK1; PIK3CB |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 2.730E-04 | 1.009E-03 | PIK3CA; MAPK1; PIK3CB; HIF1A |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 3.780E-04 | 1.336E-03 | PIK3CA; MAPK1; PIK3CB; PTGS2 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 2.942E-04 | 1.063E-03 | PIK3CA; MAPK1; PIK3CB; HIF1A |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 5.256E-04 | 1.706E-03 | PIK3CA; MAPK1; PIK3CB; TP53 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 5.256E-04 | 1.706E-03 | PIK3CA; MAPK1; PIK3CB; TP53 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 7.520E-04 | 2.391E-03 | PIK3CA; SYK; MAPK1; PIK3CB |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 7.736E-04 | 2.412E-03 | PIK3CA; MAPK1; PIK3CB; TP53 |
| hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 8.179E-04 | 2.501E-03 | PIK3CA; SYK; MAPK1; PIK3CB |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 8.408E-04 | 2.522E-03 | PIK3CA; CSNK2A1; PIK3CB; TP53 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.095E-03 | 3.053E-03 | PIK3CA; MAPK1; PIK3CB; TP53 |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 1.040E-03 | 2.953E-03 | PIK3CA; SYK; MAPK1; PIK3CB |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 9.120E-04 | 2.685E-03 | PTPN1; PIK3CA; MAPK1; PIK3CB |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.465E-03 | 3.948E-03 | PIK3CA; MAPK1; PIK3CB; PTGS2 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.834E-03 | 4.781E-03 | APP; MAPK1; MAPT; HSD17B10 |
| hsa05034 | Alcoholism_Homo sapiens_hsa05034 | 2.310E-03 | 5.830E-03 | HDAC2; MAOA; MAPK1; HDAC8 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 2.357E-03 | 5.856E-03 | HDAC2; HPGD; TP53; ELANE |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 4.090E-03 | 9.008E-03 | SYK; PIK3CA; MAPK1; PIK3CB; TP53 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 3.382E-03 | 7.908E-03 | PIK3CA; MAPK1; PIK3CB; TSHR |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 3.500E-03 | 8.065E-03 | PIK3CA; ALOX12; PIK3CB |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 3.112E-03 | 7.384E-03 | PIK3CA; PIK3CB; TP53 |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 2.499E-03 | 6.112E-03 | PIK3CA; MAPK1; PIK3CB |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 8.074E-03 | 1.584E-02 | MAPK1; MAPT; TP53; CDC25B |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 1.033E-03 | 2.953E-03 | HDAC2; PIK3CA; PIK3CB |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 4.961E-03 | 1.038E-02 | PIK3CA; MAPK1; PIK3CB |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 4.362E-03 | 9.373E-03 | PIK3CA; MAPK1; PIK3CB |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 3.019E-03 | 7.273E-03 | SYK; CSNK2A1; PTGS2 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 8.406E-03 | 1.610E-02 | POLB; PIK3CA; PIK3CB; TP53 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 4.716E-03 | 9.997E-03 | PTPN1; PIK3CA; PIK3CB |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 4.136E-03 | 9.008E-03 | PIK3CA; MAPK1; PIK3CB |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 4.136E-03 | 9.008E-03 | PIK3CA; MAPK1; PIK3CB |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.572E-03 | 4.167E-03 | PTPN1; CSNK2A1; MAPK1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 5.012E-04 | 1.696E-03 | CYP1A1; CYP1B1; PTGS2 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.395E-03 | 3.826E-03 | ABCB1; CA2; CYP3A4 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 5.879E-03 | 1.198E-02 | PIK3CA; MAPK1; PIK3CB |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 1.302E-02 | 2.379E-02 | PIK3CA; PIM1; PIK3CB |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 8.170E-03 | 1.584E-02 | PIK3CA; MAPK1; PIK3CB |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 6.741E-03 | 1.357E-02 | HDAC2; TP53; CDC25B |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 1.092E-02 | 2.019E-02 | PIK3CA; MAPK1; PIK3CB |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 9.764E-03 | 1.826E-02 | PIK3CA; MAPK1; PIK3CB |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 1.509E-02 | 2.726E-02 | PIK3CA; MAPK1; PIK3CB |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.708E-02 | 3.017E-02 | PIK3CA; MAPK1; PIK3CB |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 2.394E-04 | 9.431E-04 | PIK3CA; MAPK1; PIK3CB |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 4.442E-04 | 1.535E-03 | PIK3CA; MAPK1; PIK3CB |
| hsa05016 | Huntington's disease_Homo sapiens_hsa05016 | 2.207E-02 | 3.733E-02 | HDAC2; HTT; TP53 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 2.033E-02 | 3.540E-02 | PIK3CA; MAPK1; PIK3CB |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 2.777E-02 | 4.552E-02 | PIK3CA; MAPK1; PIK3CB |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 2.879E-02 | 4.671E-02 | PIK3CA; MAPK1; PIK3CB |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 2.483E-02 | 4.113E-02 | PIK3CA; MAPK1; PIK3CB |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 2.442E-02 | 4.087E-02 | PIK3CA; PIK3CB |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 2.158E-02 | 3.689E-02 | MAPK1; PTGS2 |
| hsa00562 | Inositol phosphate metabolism_Homo sapiens_hsa00562 | 2.049E-02 | 3.540E-02 | PIK3CA; PIK3CB |
| hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 8.592E-03 | 1.626E-02 | PIK3CA; PIK3CB |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 7.173E-03 | 1.426E-02 | MAPK1; TP53 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 3.637E-03 | 8.262E-03 | MAPK1; TP53 |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 5.267E-03 | 1.088E-02 | MAOA; TYR |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 2.294E-03 | 5.830E-03 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.541E-02 | 2.752E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ELANE; PTGS2; SYK; PTGS1 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | ELANE |
| NA: NA | Myocardial ischaemia-reperfusion injury | NA | ELANE |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PIK3CA; TP53 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; PTGS2; PTGS2; PTGS2; PTGS1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | TYR; ELANE; PTGS2; PTGS2; PTGS2; PTGS2; SYK |
| NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2; PTGS1 |
| NA: NA | Edema | NA | CA2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2 |
| NA: NA | Acute respiratory distress syndrome | NA | ELANE; ELANE; ELANE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | ABCB1 |
| C00-D49: Neoplasms | Melanoma | C43 | TYR |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; SYK |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; SLC6A2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | PTGS1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | SLC6A2; SLC6A2; SLC6A2; SLC6A2; MAOA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | HDAC2; PTGS1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| C00-D49: Neoplasms | Glioma | C71 | APP |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | ELANE; ELANE |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; SYK |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | SLC6A2; SLC6A2 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1; CYP2C9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| A00-B99: Certain infectious and parasitic diseases | Septic shock | A41.9 | ELANE |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ELANE; PTGS2; SYK; SYK |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; PTGS2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | SLC6A2 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | PIK3CB; SYK |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; PTGS1 |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ELANE; ELANE |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | SLC6A2 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; MAOA |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | SLC6A2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS1 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1; ESR1 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| J00-J99: Diseases of the respiratory system | Bronchiectasis | J47, Q33.4 | ELANE |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cancer pain | R52, G89 | SLC6A2 |
| C00-D49: Neoplasms | Cancer | C00-C96 | ABCB1; HIF1A; PIK3CA; PIK3CB; CA1; TP53; CA9; ESR1; ESR1; MAPK1; PIM1; NQO2; HDAC8; PTGS2; SYK; CDC25B; APP; CSNK2A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | SYK |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | SLC6A2; MAOA; MAOA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; PTGS2; MAPT; APP |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| J00-J99: Diseases of the respiratory system | Pulmonary emphysema | J43 | ELANE |
| J00-J99: Diseases of the respiratory system | Pulmonary disease | J00-J99 | ELANE |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | SLC6A2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; SLC6A2; MAOA |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; ESR1; ESR1; NQO2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS2; PTGS2; PTGS1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; APP |
| C00-D49: Neoplasms | Neuroblastoma | C74.1, C74.9, C75.4, C75.5, D35.0, D35.5, D35.6, D44.6, D44.7 | SLC6A2 |
| C00-D49: Neoplasms | Neuroendocrine cancer | C7A | SLC6A2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; PTGS2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | ABCB1; HIF1A; PIK3CA; PIK3CB; TP53; CA9; MAPK1; SYK |
| J00-J99: Diseases of the respiratory system | Mucolytic | J00-J99 | ELANE |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | ABCB1; PTGS2 |
| J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | ELANE; ELANE; ELANE |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; SLC6A2 |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |